CODX vs NBIX
Co-Diagnostics, Inc. Common Stock (CODX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CODX currently screens at market cap $31.4M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CODX and NBIX stock pages for the full models.
Not investment advice.